Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b-2 dose-escalation study.
暂无分享,去创建一个
S. Jagannath | A. Jakubowiak | S. Lonial | R. Vij | P. Richardson | D. Reece | P. Moreau | T. Facon | J. Zonder | A. Singhal | D. White | M. Raab | L. Benboubker | E. Bleickardt | L. Tsao | K. Anderson | Marc-Steffen Raab | Kenneth Anderson